APO-PANTOPRAZOLE TABLET (DELAYED-RELEASE)

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

PANTOPRAZOLE (PANTOPRAZOLE SODIUM)

Предлага се от:

APOTEX INC

АТС код:

A02BC02

INN (Международно Name):

PANTOPRAZOLE

дозиране:

40MG

Лекарствена форма:

TABLET (DELAYED-RELEASE)

Композиция:

PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40MG

Начин на приложение:

ORAL

Броя в опаковка:

100/500

Вид предписание :

Prescription

Терапевтична област:

PROTON-PUMP INHIBITORS

Каталог на резюме:

Active ingredient group (AIG) number: 0133229001; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2008-03-05

Данни за продукта

_APO-PANTOPRAZOLE (pantoprazole sodium) _
_ _
_Page 1 of 53 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
APO-PANTOPRAZOLE
Pantoprazole Sodium Delayed-Release Tablets
Delayed-Release Tablets, 20 mg and 40 mg pantoprazole (as pantoprazole
sodium), Oral
USP
Proton Pump Inhibitor
APOTEX INC.
150 Signet Drive
Toronto, Ontario M9L 1T9
Date of Initial Authorization:
March 5, 2008
Date of Revision:
November 8, 2023
Submission Control Number: 273811
_APO-PANTOPRAZOLE (pantoprazole sodium) _
_ _
_Page 2 of 53 _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism
06/2023
7 WARNINGS AND PRECAUTIONS,
Immune
06/2023
7 WARNINGS AND PRECAUTIONS, Skin
06/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
....................................................................................................................
4
1.1
Pediatrics
......................................................................................................................
4
1.2
Geriatrics
......................................................................................................................
4
2
CONTRAINDICATIONS
.......................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.......................................................................................
5
4.1
Dosing Considerations
..................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
...................................................